Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: NPC

October 5, 2022 CD as API / CD derivatives

Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC

Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it

Continue reading

June 30, 2021 CD as API / Pharma applications

Recent reviews on cyclodextrins against SARS-CoV-2

Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

September 7, 2020 CD as API / Pharma applications

Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity

Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and

Continue reading

March 26, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo

Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

February 6, 2020 CD as API / CD derivatives / Pharma applications / Uncategorized

Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease

Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

October 25, 2019 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced

Continue reading

February 20, 2019 CD as API / CD derivatives

CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™

CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical

Continue reading

December 6, 2018 CD derivatives / Drug delivery / Events / Pharma applications

Opinion leaders of CD society getting together in Budapest

In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from

Continue reading

September 22, 2018 CD as API / Pharma applications

Therapeutic potential for cyclodextrin‐based macromolecular systems in NPC

A paper has just come out in Macromolecular Rapid Communications highlighting the potential benefits of cyclodextrin-based macromolecular systems as cholesterol-mopping

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • 7th European Cyclodextrin Conference
  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Small anticancer drug release by light
  • Patent application on reduction of envelope viral particle number in a composition containing cyclodextrin

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (199)
  • CD derivatives (251)
  • Cosmetics and toilettry (21)
  • Drug delivery (416)
  • E-ducation (54)
  • Environmental (76)
  • Events (158)
  • Food (120)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (13)
  • Non-pharma applications (209)
  • Other industrial use (58)
  • Pharma applications (677)
  • Supramolecular systems (25)
  • Uncategorized (41)

Top Posts

  • Lanosterol eye drops for cataract treatment
  • 7th European Cyclodextrin Conference
  • Organic molecules revealed in Mars’s Bagnold Dunes by Curiosity’s derivatization experiment
  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • GRAS status of CD derivatives
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • International Symposium of Drug Delivery Systems (SDDS-2022)
  • Egg-Free Bakery - Recommendation from Wacker
  • Ivermectin against COVID-19
  • Cyclodextrins as flame retardants

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 522 other subscribers
 

Loading Comments...